je.st
news
Tag: accepts
Ratan Tata accepts Sarkar's invitation
2015-07-08 01:42:15| Steel - Topix.net
Agartala, July 7: Ratan Tata will be in Tripura for a day on Thursday in response to an invitation from chief minister Manik Sarkar. He will be accompanied by a team of executives of the Tata Group.
Tags: accepts
invitation
tata
ratan
U.S. Navy Accepts Third Lockheed Martin-Built MUOS Communications Satellite
2015-06-05 08:08:17| rfglobalnet Home Page
Following successful completion of on-orbit testing, the U.S. Navy accepted the third Lockheed Martin-built Mobile User Objective System (MUOS) satellite.
Tags: communications
satellite
accepts
navy
US Navy accepts third Lockheed Martins MUOS-3 satellite
2015-06-04 01:00:00| Naval Technology
The US Navy has accepted the third Lockheed Martin mobile user objective system (MUOS) satellite, following the completion of on-orbit testing.
Tags: satellite
accepts
navy
martins
Desktop 3D Printer accepts remote input and control.
2015-06-03 14:31:05| Industrial Newsroom - All News for Today
Able to be operated by remote control through mobile device, CTC Giant supports Wi-Fi® functionality as well as Android®- and iOS®-compatible apps based on Ultimaker technology. Seamless, all-steel printer comes with Cura slicing software, uses molten accumulation forming principle and ABS plastic (18 colors), and features single sprinkler printer head. Max print size is 305 x 305 x 405 mm, max print speed is 180 mm/sec, and positioning accuracy is 10 microns (X/Y) and 1 micron (Y).
Tags: control
printer
input
desktop
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review
2015-06-01 22:34:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-001 Data Served as the Basis for U.S. FDA Filing and Breakthrough Therapy Designation in Advanced NSCLC Across Histologies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-containing chemotherapy and an FDA-approved therapy for EGFR or ALK genomic tumor aberrations, if present. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] next »